H.C. Wainwright raised the firm’s price target on BiomX (PHGE) to $21 from $2 and keeps a Buy rating on the shares. The new target reflects the company’s 1-for-10 reverse-split in August 2024. BiomX also announced positive results from its Phase 2 trial of BX211 for diabetic foot osteomyelitis associated with S. aureus, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHGE: